| Consensus statements | Strength of advice |
|---|---|
| For patients on oral anticoagulation for stroke prophylaxis in AF in case of severe infection, we advise to switch to low- or intermediate-dose LMWH when platelets drop between 100 and 30 × 109/L (only if INR is <2.0 for those on a VKA).138,139 |  |
| We advise to interrupt anticoagulant treatment for platelet count <30 × 109/L. For patients with VTE, the dose of heparin should be based on the severity of the infection and whether the indication is a recent thromboembolic event.66 |  |
| For patients with VTE within 1 month, it may be appropriate to remain on full anticoagulation, preferably with LMWH, split into two daily doses. |  |
| We advise to check for clinically relevant drug–drug interactions in patients treated with OAC based on ongoing antimicrobial treatment and on the specific anticoagulant drug in use.148 | |
| We advise to treat patients with high degree of SIC with gastroprotective agents, preferably PPIs.19,93,99,102,103 | |
| In patients with a long-term VKA indication, we advise to intensify INR monitoring or switch to heparin during hospitalization.71,141 | |
| Consensus statements | Strength of advice |
|---|---|
| For patients on oral anticoagulation for stroke prophylaxis in AF in case of severe infection, we advise to switch to low- or intermediate-dose LMWH when platelets drop between 100 and 30 × 109/L (only if INR is <2.0 for those on a VKA).138,139 | |
| We advise to interrupt anticoagulant treatment for platelet count <30 × 109/L. For patients with VTE, the dose of heparin should be based on the severity of the infection and whether the indication is a recent thromboembolic event.66 | |
| For patients with VTE within 1 month, it may be appropriate to remain on full anticoagulation, preferably with LMWH, split into two daily doses. | |
| We advise to check for clinically relevant drug–drug interactions in patients treated with OAC based on ongoing antimicrobial treatment and on the specific anticoagulant drug in use.148 | |
| We advise to treat patients with high degree of SIC with gastroprotective agents, preferably PPIs.19,93,99,102,103 | |
| In patients with a long-term VKA indication, we advise to intensify INR monitoring or switch to heparin during hospitalization.71,141 | |
| Consensus statements | Strength of advice |
|---|---|
| For patients on oral anticoagulation for stroke prophylaxis in AF in case of severe infection, we advise to switch to low- or intermediate-dose LMWH when platelets drop between 100 and 30 × 109/L (only if INR is <2.0 for those on a VKA).138,139 | |
| We advise to interrupt anticoagulant treatment for platelet count <30 × 109/L. For patients with VTE, the dose of heparin should be based on the severity of the infection and whether the indication is a recent thromboembolic event.66 | |
| For patients with VTE within 1 month, it may be appropriate to remain on full anticoagulation, preferably with LMWH, split into two daily doses. | |
| We advise to check for clinically relevant drug–drug interactions in patients treated with OAC based on ongoing antimicrobial treatment and on the specific anticoagulant drug in use.148 | |
| We advise to treat patients with high degree of SIC with gastroprotective agents, preferably PPIs.19,93,99,102,103 | |
| In patients with a long-term VKA indication, we advise to intensify INR monitoring or switch to heparin during hospitalization.71,141 | |
| Consensus statements | Strength of advice |
|---|---|
| For patients on oral anticoagulation for stroke prophylaxis in AF in case of severe infection, we advise to switch to low- or intermediate-dose LMWH when platelets drop between 100 and 30 × 109/L (only if INR is <2.0 for those on a VKA).138,139 | |
| We advise to interrupt anticoagulant treatment for platelet count <30 × 109/L. For patients with VTE, the dose of heparin should be based on the severity of the infection and whether the indication is a recent thromboembolic event.66 | |
| For patients with VTE within 1 month, it may be appropriate to remain on full anticoagulation, preferably with LMWH, split into two daily doses. | |
| We advise to check for clinically relevant drug–drug interactions in patients treated with OAC based on ongoing antimicrobial treatment and on the specific anticoagulant drug in use.148 | |
| We advise to treat patients with high degree of SIC with gastroprotective agents, preferably PPIs.19,93,99,102,103 | |
| In patients with a long-term VKA indication, we advise to intensify INR monitoring or switch to heparin during hospitalization.71,141 | |
